Fresenius Medical Care AG

Fresenius Medical Care AG

21.86
USD
-0.17
(-0.77%)
2.24EPS
13.15P/E
11.65BMarket Cap
Feb 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
17.36
21.46
25.3
27.01
28.91
26.9
28.78
30.27
29.97
32.97
33.04
32.84
33.59
35.54
Basic EPS, GAAP
1.32
1.42
1.56
1.86
2.08
3.22
1.98
1.97
1.65
1.14
0.85
0.91
1.67
1.5
Free Cash Flow per Basic Share
1.53
1.26
1.49
1.63
2.03
1.63
2.37
5.39
2.78
2.45
3.3
2.87
3.02
3.28
Dividend per Share
0.35
0.43
0.39
0.4
0.48
0.53
0.58
0.6
0.67
0.67
0.56
0.59
0.72
- -
Book Value per Share
10.77
12.84
14.76
16.24
15.97
19.1
19.98
19.08
21.6
23.76
23.13
24.76
23.75
24.57
Tangible Book Value per Share
-3.71
-6.13
-5.94
-6.15
-4.83
-1.84
-5.82
-5.32
-5.31
-5.64
-4.06
-3.34
-2.71
-4.77
Basic Weighted Avg Shares
610
607
611
613
615
615
607
590
588
588
589
589
584
548
Sales/Revenue/Turnover
10,580
13,019
15,455
16,570
17,784
16,547
17,477
17,859
17,619
19,398
19,454
19,336
19,628
19,479
Operating Margin (%)
15.26
14.08
13.59
14.1
12.76
13.03
12.56
12.37
10.55
7.5
7.59
7.59
9.31
9.93
Depreciation Expense
469
575
648
702
735
790
1,593
1,786
1,624
1,838
1,752
1,742
1,500
1,633
Net Income, GAAP
804
860
955
1,144
1,280
1,982
1,200
1,164
969
673
499
538
978
823
Effective Tax Rate (%)
32.04
31.66
31.82
30.58
22.18
18.67
21.83
25.85
22.45
26.65
29.1
29.9
21.22
22.61
Profit Margin (%)
7.6
6.6
6.18
6.9
7.2
11.98
6.86
6.52
5.5
3.47
2.57
2.78
4.98
4.22
Working Capital
1,979
2,665
2,395
1,585
1,074
1,579
106
1,219
710
1,736
2,590
2,263
1,653
-66
LT Debt
5,610
7,413
7,183
6,833
5,795
5,046
10,525
10,683
10,735
11,176
10,489
9,761
8,598
7,912
Total Equity
6,869
8,247
9,600
11,051
10,828
12,902
13,227
12,331
13,979
15,449
14,827
15,769
14,283
13,757
Return on Invested Capital (%)
8.34
8.63
8.57
9.02
9.75
12.72
7.43
6.55
5.47
3.93
3.46
3.6
5.49
5.41
Return on Capital (%)
7.01
6.63
6.03
6.35
7.1
10.86
5.67
4.63
3.82
2.56
2.04
2.31
4.12
3.51
Return on Common Equity (%)
11.96
11.89
11.36
12.03
12.93
18.37
10.12
10.05
8.11
5.05
3.61
3.82
7.02
6.39

Capital Structure

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2,389
2,325
2,974
LT Borrowings
5,741
5,825
5,148
LT Finance Leases
2,899
2,814
2,764
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
542
534
521
Market Capitalization
10,577
10,567
10,282

Working Capital

EUR

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,108
7,689
7,840
Cash, Cash Equivalents & STI
1,623
1,449
1,483
Accounts Receivable, Net
3,582
3,350
3,314
Inventories
2,303
2,332
2,413
Total Current Liabilities
6,730
7,178
7,905
Payables & Accruals
1,042
1,125
1,194
ST Debt
2,389
2,325
2,974
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.48%
3.36%
-9.42%
Free Cash Flow
14.54%
-6.84%
4.67%
Net Income, GAAP
6.06%
3.3%
81.88%
Sales/Revenue/Turnover
2.53%
1.99%
1.51%
Total Cash Common Dividend
6.51%
4.58%
21.01%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,725
4,766
4,760
5,085
19,336
2025
4,881
4,792
4,885
5,070
19,628
2026
4,612
4,861
4,937
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.32
0.36
0.11
0.91
2025
0.26
0.38
0.47
0.57
1.67
2026
0.21
0.41
0.3
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.59
2025
- -
- -
- -
- -
0.72
2026
- -
- -
- -
- -
- -

Company Description

CEO
Shervin Joe Korangy
Full Time Employees
111,024
Sector
Health services
Industry
Medical/Nursing services
Address
Else-KrOener Strasse 1 Bad Homburg Germany 61352
IPO Date
Oct 2, 1996
Business
Fresenius Medical Care AG & Co. KGaA is the world's leading provider of products and services for individuals with chronic kidney disease and end-stage renal disease, operating a global network of approximately 3,700 dialysis clinics that served more than 299,000 patients as of December 31, 2024. The company offers dialysis products including machines, dialyzers, water treatment systems such as reverse osmosis units, and related disposables; renal pharmaceuticals for treating anemia, mineral bone disorders, and other kidney disease complications; acute care services encompassing continuous renal replacement therapy for acute kidney injury; vascular access management for arteriovenous fistulas and grafts; and home-based hemodialysis and peritoneal dialysis solutions. It maintains around 40 production sites across all continents and conducts worldwide research and development to advance renal therapies and technologies. Fresenius Medical Care AG & Co. KGaA serves dialysis clinics, hospitals, intensive care units, vascular surgeons, and patients requiring in-center or at-home treatments, with a focus on value-based care delivery in North America and other regions. Founded in 1996 through the merger of Fresenius AG and National Medical Care, the company is headquartered in Bad Homburg v. d. Höhe, Germany, with significant U.S. operations including a major facility in Waltham, Massachusetts. It operates as a separately listed entity following strategic initiatives by parent Fresenius SE & Co. KGaA to deconsolidate it into an AG legal form, enhancing governance flexibility and focus on kidney care. Among recent developments, Fresenius Medical Care reported accelerated revenue growth in the third quarter of 2025, building on momentum from value-based care expansions in 2024 and 2023. The company initiated a share buyback program in June 2025, while its parent Fresenius SE plans corresponding share sales to optimize capital structure. Additionally, Fresenius received a €400 million loan from the European Investment Bank in September 2025 to support R&D, innovation, and manufacturing capacity expansion for medical products and biosimilars in Europe.

Company News

  • Dialysis Giants DaVita and Fresenius Blocking Competition In Washington, Lawsuit Accuses

  • What Fresenius Medical Care AG & Co. KGaA (FMS) Said on Its Q3 Earnings Call

  • Fresenius Medical Care AG (FMS) Q3 2026 Earnings Call Transcript

  • Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook

  • Fresenius Medical cuts top end of 2026 profit outlook

  • FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI

  • Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

  • Fly Alliance to Replace Entire Flight Management System with flyExclusive's AI-Powered Contrails FMS

  • Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

  • Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Consensus Price Target of $23.57 According to Brokerages

  • Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

  • Tidal Investments LLC Buys 48,885 Shares of Fresenius Medical Care AG & Co. KGaA $FMS

  • Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

  • Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

  • Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Passes Above 200 Day Moving Average – Time to Sell?

  • 3 Cheap International Stocks to Buy

  • Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights

  • FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand